EP1363128A3 - Diagnostic de l infarctus du myocarde et syndromes coronariens aigus par la combinaison de marqueurs - Google Patents

Diagnostic de l infarctus du myocarde et syndromes coronariens aigus par la combinaison de marqueurs Download PDF

Info

Publication number
EP1363128A3
EP1363128A3 EP03010818A EP03010818A EP1363128A3 EP 1363128 A3 EP1363128 A3 EP 1363128A3 EP 03010818 A EP03010818 A EP 03010818A EP 03010818 A EP03010818 A EP 03010818A EP 1363128 A3 EP1363128 A3 EP 1363128A3
Authority
EP
European Patent Office
Prior art keywords
markers
myocardial infarction
acute coronary
diagnosis
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP03010818A
Other languages
German (de)
English (en)
Other versions
EP1363128B1 (fr
EP1363128B8 (fr
EP1363128A2 (fr
Inventor
Christian Prof. Dr. Hamm
Eberhard Dr. Spanuth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29270797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1363128(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Publication of EP1363128A2 publication Critical patent/EP1363128A2/fr
Publication of EP1363128A3 publication Critical patent/EP1363128A3/fr
Publication of EP1363128B1 publication Critical patent/EP1363128B1/fr
Application granted granted Critical
Publication of EP1363128B8 publication Critical patent/EP1363128B8/fr
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21S—NON-PORTABLE LIGHTING DEVICES; SYSTEMS THEREOF; VEHICLE LIGHTING DEVICES SPECIALLY ADAPTED FOR VEHICLE EXTERIORS
    • F21S4/00—Lighting devices or systems using a string or strip of light sources
    • F21S4/20—Lighting devices or systems using a string or strip of light sources with light sources held by or within elongate supports
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21W—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES F21K, F21L, F21S and F21V, RELATING TO USES OR APPLICATIONS OF LIGHTING DEVICES OR SYSTEMS
    • F21W2121/00—Use or application of lighting devices or systems for decorative purposes, not provided for in codes F21W2102/00 – F21W2107/00
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21Y—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES F21K, F21L, F21S and F21V, RELATING TO THE FORM OR THE KIND OF THE LIGHT SOURCES OR OF THE COLOUR OF THE LIGHT EMITTED
    • F21Y2103/00—Elongate light sources, e.g. fluorescent tubes
    • F21Y2103/10—Elongate light sources, e.g. fluorescent tubes comprising a linear array of point-like light-generating elements
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F21—LIGHTING
    • F21Y—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES F21K, F21L, F21S and F21V, RELATING TO THE FORM OR THE KIND OF THE LIGHT SOURCES OR OF THE COLOUR OF THE LIGHT EMITTED
    • F21Y2115/00—Light-generating elements of semiconductor light sources
    • F21Y2115/10—Light-emitting diodes [LED]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Electrotherapy Devices (AREA)
  • Peptides Or Proteins (AREA)
EP03010818A 2002-05-14 2003-05-14 Diagnostic de l'infarctus du myocarde et syndromes coronariens aigus par la combinaison de marqueurs Revoked EP1363128B8 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38041302P 2002-05-14 2002-05-14
US380413P 2002-05-14

Publications (4)

Publication Number Publication Date
EP1363128A2 EP1363128A2 (fr) 2003-11-19
EP1363128A3 true EP1363128A3 (fr) 2004-01-28
EP1363128B1 EP1363128B1 (fr) 2006-06-28
EP1363128B8 EP1363128B8 (fr) 2006-10-18

Family

ID=29270797

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03010818A Revoked EP1363128B8 (fr) 2002-05-14 2003-05-14 Diagnostic de l'infarctus du myocarde et syndromes coronariens aigus par la combinaison de marqueurs

Country Status (13)

Country Link
US (1) US7790397B2 (fr)
EP (1) EP1363128B8 (fr)
JP (1) JP3783002B2 (fr)
KR (1) KR20030088380A (fr)
CN (1) CN1459633A (fr)
AT (1) ATE331960T1 (fr)
AU (1) AU2003204190A1 (fr)
BR (1) BR0301719A (fr)
CA (1) CA2428760A1 (fr)
DE (1) DE50304023D1 (fr)
ES (1) ES2268215T3 (fr)
MX (1) MXPA03004105A (fr)
PL (1) PL360130A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524635B2 (en) * 2003-04-17 2009-04-28 Biosite Incorporated Methods and compositions for measuring natriuretic peptides and uses thereof
EP1322957B1 (fr) * 2001-05-04 2009-08-12 Biosite Incorporated Marqueurs diagnostiques de syndromes coronaires aigus et leurs methodes d'utilisation
DE10351238A1 (de) * 2003-11-03 2005-06-02 Roche Diagnostics Gmbh Diagnosestellung von akuten myokardialen, ischämischen Erkrankungen durch Kombination von Markern
ATE403157T1 (de) * 2004-03-15 2008-08-15 Hoffmann La Roche Verwendung des bnp-art und anp-art peptiden für das festsetzen der gefahren von herzgefäss- komplikationen als folge der volumenüberlastung
EP1722232A1 (fr) * 2005-05-09 2006-11-15 F.Hoffmann-La Roche Ag Dispositifs et procédés de diagnostics ou de prévoir d'un stade précoce des dysfonctionnements cardiaques
EP1731910A1 (fr) * 2005-06-07 2006-12-13 F. Hoffmann-La Roche Ag Utilisation de NT-proANP et NT-proBNP pour le diagnostic de maladies cardiaques
WO2007085411A1 (fr) * 2006-01-25 2007-08-02 Roche Diagnostics Gmbh Anticorps anti-troponine et risque cardiovasculaire
EP1816477A1 (fr) * 2006-02-06 2007-08-08 F. Hoffmann-la Roche AG Utilisation de peptides natriurétiques et niveaux du facteur de croissance du placenta pour la stratification de risque de personnes choisies pour l'essai de contraintes cardiaques
JP6325022B2 (ja) * 2006-04-04 2018-05-16 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
JP5308328B2 (ja) * 2006-04-04 2013-10-09 シングレックス，インコーポレイテッド トロポニンの分析のための高感度のシステムおよび方法
US7838250B1 (en) 2006-04-04 2010-11-23 Singulex, Inc. Highly sensitive system and methods for analysis of troponin
DK2848938T3 (da) * 2006-04-24 2017-11-13 Critical Care Diagnostics Inc Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
EP1884777A1 (fr) * 2006-08-04 2008-02-06 Medizinische Hochschule Hannover Moyens et procédés d'évaluation du risque d'interventions cardiaques basées sur GDF-15
MX2009000914A (es) * 2006-08-04 2009-06-18 Hannover Med Hochschule Medios y metodos para evaluar el riesgo de intervenciones cardiacas basadas en el factor 15 de diferenciacion del crecimiento.
EP1887361A1 (fr) * 2006-08-07 2008-02-13 Bio-Rad Pasteur Procédé de prédiction des événements vasculaires
EP1890154B1 (fr) * 2006-08-16 2012-07-04 F. Hoffmann-La Roche AG Troponine cardiaque servant d'indicateur de maladie avancée des artères coronaires et de ses complications
EP1890153A1 (fr) 2006-08-16 2008-02-20 F. Hoffman-la Roche AG Troponine cardiaque servant d'indicateur de maladie avancée des artères coronaires
EP2084543B1 (fr) * 2006-10-26 2017-10-18 B.R.A.H.M.S GmbH Stratification des risques du syndrome coronarien aigu au moyen de fragments et de peptides partiels de la provasopressine, en particulier de la copeptine ou de la neurophysine ii
DE102006050497A1 (de) * 2006-10-26 2008-04-30 Brahms Aktiengesellschaft Risikostratifizierung des akuten Koronarsyndroms mittels Fragmenten / Teilpeptiden des proVasopressins, insbesondere Copeptin oder Neurophysin II
DE102006053442A1 (de) * 2006-11-12 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Infektionen und chronischen Erkrankungen der Atemwege und Lunge mittels proVasopressin, insbesondere Copeptin oder Neurophysin II
EP2089719A2 (fr) * 2006-11-21 2009-08-19 Roche Diagnostics GmbH Moyens et procédés d'optimisation d'approches diagnostiques et thérapeutiques dans une maladie artérielle chronique basés sur la troponine t et le nt-probnp
DE102006058266A1 (de) * 2006-12-08 2008-06-12 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz mittels Neurophysin
DE102006060835A1 (de) * 2006-12-22 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung des akuten Koronarsyndroms mittels CT-proET-1 in Kombination mit NT-proBNP
DE102007010834A1 (de) * 2007-03-03 2008-09-04 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Herzinsuffizienz für NYHA I Patienten
DE102007022367A1 (de) * 2007-05-07 2008-11-20 B.R.A.H.M.S Ag Verfahren zur Bestimmung von aminoterminalen pro-ANP bei übergewichtigen Patienten
EP2201383B1 (fr) 2007-10-10 2014-01-15 Roche Diagnostics GmbH Moyens et procédés de surveillance de l'infarctus du myocarde et son traitement
JP2011528115A (ja) * 2008-07-14 2011-11-10 エフ．ホフマン−ラ ロシュ アーゲー 心不全を有する患者の診断、モニター及び治療の選択のためのマルチマーカーパネル
JP5753159B2 (ja) * 2009-05-05 2015-07-22 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化
WO2010144358A1 (fr) 2009-06-08 2010-12-16 Singulex, Inc. Groupes de biomarqueurs très sensibles
DK2498796T3 (en) 2009-11-09 2018-03-05 Aal Scient Inc HEART DISEASE TREATMENT
WO2011057251A2 (fr) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Traitement d'une cardiopathie
CA2780301A1 (fr) * 2009-11-13 2011-05-19 Bg Medicine, Inc. Facteurs de risque et prevision d'un infarctus du myocarde
AU2011249908A1 (en) 2010-05-06 2012-11-22 Singulex, Inc. Methods for diagnosing, staging, predicting risk for developing and identifying treatment responders for rheumatoid arthritis
EP2663869A1 (fr) * 2011-01-13 2013-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et trousses permettant de prédire le risque de survenue d'un événement cardiovasculaire chez un sujet
US20140273273A1 (en) 2012-11-01 2014-09-18 Christie Mitchell Ballantyne Biomarkers to improve prediction of heart failure risk

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002023191A1 (fr) * 2000-09-12 2002-03-21 University Of Sydney Dosage diagnostique
WO2002083913A1 (fr) * 2001-04-13 2002-10-24 Biosite Diagnostics, Inc. Utilisation du peptide natriuretique de type b en tant qu'indicateur pronostique des syndromes coronariens aigus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922873A1 (de) 1989-04-25 1990-10-31 Boehringer Mannheim Gmbh Spezifische antikoerper gegen troponin t, ihre herstellung und verwendung in einem reagenz zur bestimmung von hermuskelnekrosen
US5580722A (en) 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
SE8904407L (sv) 1989-12-29 1991-06-30 Qingpingfeng Medikament foer behandling av hjaertsvikt
GB9211686D0 (en) 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
JP5264026B2 (ja) 1997-06-10 2013-08-14 エルパス・インコーポレイテッド 心疾患の早期発見のための方法
US6117644A (en) 1998-06-04 2000-09-12 Ottawa Heart Institute Research Corporation Predicting and detecting cardiac allograft rejection
PL204235B1 (pl) 1999-01-29 2009-12-31 Roche Diagnostics Gmbh Sposób wykrywania natywnego N-końcowego proBNP, zastosowanie tego sposobu, zastosowanie zrekombinowanego N-końcowego proBNP, przeciwciała przeciw zrekombinowanemu N-końcowemu proBNP, linie komórkowe i sposoby wytwarzania przeciwciał poliklonalnych i monoklonalnych
EP1322957B1 (fr) 2001-05-04 2009-08-12 Biosite Incorporated Marqueurs diagnostiques de syndromes coronaires aigus et leurs methodes d'utilisation
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002023191A1 (fr) * 2000-09-12 2002-03-21 University Of Sydney Dosage diagnostique
WO2002083913A1 (fr) * 2001-04-13 2002-10-24 Biosite Diagnostics, Inc. Utilisation du peptide natriuretique de type b en tant qu'indicateur pronostique des syndromes coronariens aigus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAIR JOHANNES ET AL: "The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure", CLINICAL CHEMISTRY AND LABORATORY MEDICINE, vol. 39, no. 7, July 2001 (2001-07-01), pages 571 - 588, XP008024871, ISSN: 1434-6621 *
SABATINE MARC S ET AL: "Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide", CIRCULATION, vol. 105, no. 15, 16 April 2002 (2002-04-16), pages 1760 - 1763, XP002262207, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
JP2004037455A (ja) 2004-02-05
PL360130A1 (en) 2003-11-17
KR20030088380A (ko) 2003-11-19
ES2268215T3 (es) 2007-03-16
DE50304023D1 (de) 2006-08-10
EP1363128B1 (fr) 2006-06-28
AU2003204190A1 (en) 2003-12-04
US20100173321A1 (en) 2010-07-08
BR0301719A (pt) 2004-08-24
CA2428760A1 (fr) 2003-11-14
EP1363128B8 (fr) 2006-10-18
MXPA03004105A (es) 2004-10-15
ATE331960T1 (de) 2006-07-15
JP3783002B2 (ja) 2006-06-07
EP1363128A2 (fr) 2003-11-19
US7790397B2 (en) 2010-09-07
CN1459633A (zh) 2003-12-03

Similar Documents

Publication Publication Date Title
EP1363128A3 (fr) Diagnostic de l infarctus du myocarde et syndromes coronariens aigus par la combinaison de marqueurs
EP2113774A3 (fr) PIGF et Flt-1 comme paramètre pronostique pour des maladies cardiovasculaires
Casale et al. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings.
Pettersson et al. Changes in high-frequency QRS components are more sensitive than ST-segment deviation for detecting acute coronary artery occlusion
Buckingham et al. Effect of conduction defects on the signal-averaged electrocardiographic determination of late potentials
Gheenfield et al. The clinical investigation and management of chest pain in an emergency department: quality assessment by criteria mapping
Angeli et al. Usefulness of QRS voltage correction by body mass index to improve electrocardiographic detection of left ventricular hypertrophy in patients with systemic hypertension
ATE375517T1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
Rostoff et al. ORIGINAL ARTICLE ST segment elevation in lead aVR and coronary artery lesions in patients with acute coronary syndrome
Zema et al. Electrocardiographic poor R-wave progression: correlation with postmortem findings
D'Souza et al. The significance of the MB isoenzyme in patients with acute cardiovascular disease with a normal or borderline total CPK activity
Beker et al. Analysis of high frequency QRS potential during exercise testing in patients with coronary artery disease and in healthy subjects
Blondeel et al. Ventricular Depolarization Abnormalities and Their Role in Cardiac Risk Stratification—A Narrative Review
Fallah-Najmabadi et al. Normal values and methodologic recommendations for signal-averaged electrocardiography in children and adolescents
Vandenberg et al. Electrocardiographic criteria for diagnosis of left ventricular hypertrophy in the presence of complete right bundle branch block
Yen et al. Diagnostic and prognostic accuracy of the exercise electrocardiogram in patients with preexisting right bundle branch block
Ma et al. Fragmented QRS complex on ECG is associated with ventricular arrhythmias in patients with a prior myocardial infarction
Suszko et al. Quantifying abnormal QRS peaks using a novel time-domain peak detection algorithm: Application in patients with cardiomyopathy at risk of sudden death
Brembilla-Perrot Correlation between inducibility of sustained ventricular tachycardia and QRS duration
Laciar et al. Evaluation of myocardial damage in chagasic patients from the signal-averaged and beat-to beat analysis of the high resolution electrocardiogram
Santos et al. Surface electrocardiogram detects signs of right ventricular pressure overload among acute-decompensated heart failure with preserved ejection fraction patients
Mann et al. High prevalence of ST-elevation, early repolarization, and left ventricular hypertrophy during the eligibility assessment for an HIV vaccine trial in young, healthy Tanzanians
RU2114552C1 (ru) Способ прогнозирования отдаленного исхода инфаркта миокарда
Xia et al. Selvester scoring in patients with strict LBBB using the QUARESS software
Morawiec et al. COPeptin for diagnosis and prediction in Acute Coronary Syndrome (COPACS) Study: design and objectives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

17P Request for examination filed

Effective date: 20040305

17Q First examination report despatched

Effective date: 20040802

AKX Designation fees paid

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20060628

Ref country code: IE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: A. BRAUN, BRAUN, HERITIER, ESCHMANN AG PATENTANWAE

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: F. HOFFMANN-LA ROCHE AG

Owner name: ROCHE DIAGNOSTICS GMBH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REF Corresponds to:

Ref document number: 50304023

Country of ref document: DE

Date of ref document: 20060810

Kind code of ref document: P

GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)

Effective date: 20060817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060928

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060928

NLT2 Nl: modifications (of names), taken from the european patent patent bulletin

Owner name: F. HOFFMANN-LA ROCHE AG

Effective date: 20060809

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061128

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
REG Reference to a national code

Ref country code: IE

Ref legal event code: FD4D

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2268215

Country of ref document: ES

Kind code of ref document: T3

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: BIOSITE INCORPORATED

Effective date: 20070315

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

BERE Be: lapsed

Owner name: ROCHE DIAGNOSTICS G.M.B.H.

Effective date: 20070531

Owner name: F. HOFFMANN-LA ROCHE A.G.

Effective date: 20070531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060929

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: F. HOFFMANN-LA ROCHE AG

Free format text: F. HOFFMANN-LA ROCHE AG#GRENZACHERSTRASSE 124#4070 BASEL (CH) -TRANSFER TO- F. HOFFMANN-LA ROCHE AG#GRENZACHERSTRASSE 124#4070 BASEL (CH)

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060928

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

RDAF Communication despatched that patent is revoked

Free format text: ORIGINAL CODE: EPIDOSNREV1

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBQ Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3O

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070514

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20061229

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20060628

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

REG Reference to a national code

Ref country code: DE

Ref legal event code: R103

Ref document number: 50304023

Country of ref document: DE

Ref country code: DE

Ref legal event code: R064

Ref document number: 50304023

Country of ref document: DE

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

RDAG Patent revoked

Free format text: ORIGINAL CODE: 0009271

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT REVOKED

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20120531

Year of fee payment: 10

Ref country code: CH

Payment date: 20120427

Year of fee payment: 10

27W Patent revoked

Effective date: 20120301

GBPR Gb: patent revoked under art. 102 of the ep convention designating the uk as contracting state

Effective date: 20120301

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20120426

Year of fee payment: 10

Ref country code: FR

Payment date: 20120510

Year of fee payment: 10

REG Reference to a national code

Ref country code: DE

Ref legal event code: R107

Ref document number: 50304023

Country of ref document: DE

Effective date: 20120927

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20120517

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20060628

Ref country code: CH

Free format text: LAPSE BECAUSE OF THE APPLICANT RENOUNCES

Effective date: 20060628

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20120511

Year of fee payment: 10

REG Reference to a national code

Ref country code: AT

Ref legal event code: MA03

Ref document number: 331960

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120301

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20120426

Year of fee payment: 10

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230526